CBDS Seminar Series

Event time: 
Wednesday, November 2, 2022 - 4:00pm to 5:00pm
Location: 
TAC N203 See map
Event description: 

Olivier Elemento, PhD (Cornell Medicine)

“Reverse-engineering the tumor microenvironment using single-cell resolution imaging, machine learning and tumor organoids”

Background
Dr. Elemento is a professor of physiology and biophysics at Weill Cornell Medicine (WCM) and Cornell University. Since 2017, he has been the Director of the Caryl and Israel Englander Institute for Precision Medicine (https://eipm.weill.cornell.edu/). The Englander Institute is a multidisciplinary institute that draws over 100 faculty members from nearly all basic and clinical departments at Cornell University. The Englander Institute’s mission is to use genomics, artificial intelligence (AI), patient-derived models and other technologies to develop and bring highly personalized medicine to patients at Weill Cornell’s affiliated hospital, New York Presbyterian Hospital (NYPH) and elsewhere. The Institute also fosters patient-centered basic and clinical research in the areas of genomics, systems biology, AI and data science. Dr. Elemento is funded by numerous NIH grants, foundation grants, NIH contracts and industry alliances. He has published over 380 papers in the area of precision medicine, genomics, computational biology, artificial intelligence, systems biology and drug discovery. He has led the development of novel clinical (CLIA) genomics assays including whole-exome sequencing offered to patients at WCM/NYPH and is currently leading a large multi-cancer effort to bring patient-derived cell models (organoids) and high-throughput drug screening into clinical use at WCM/NYPH. Dr. Elemento co-founded two venture capital-funded companies: Volastra Therapeutics and OneThree Biotech.
Tags: